Hikma full-year profit doubles on strong doxycycline sales

March 12 (Reuters) - Hikma Pharmaceuticals Plc's full-year profit more than doubled helped by strong demand and higher prices for the antibiotic doxycycline that is used in the treatment bacterial infections including Lyme disease.